Your browser doesn't support javascript.
loading
Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
Argüelles Arias, Federico; Hinojosa Del Val, Joaquín; Vera Mendoza, Isabel.
Affiliation
  • Argüelles Arias F; Digestivo, H. Universitarioa Virgen Macarena, España.
  • Hinojosa Del Val J; Digestivo, Hospital de Manises.
  • Vera Mendoza I; Digestivo, Hospital Universitario Puerta de Hierro.
Rev Esp Enferm Dig ; 110(6): 407, 2018 Jun.
Article in En | MEDLINE | ID: mdl-29527903
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Biosimilar Pharmaceuticals / Infliximab / Anti-Inflammatory Agents Type of study: Guideline Limits: Humans Language: En Journal: Rev Esp Enferm Dig Journal subject: GASTROENTEROLOGIA Year: 2018 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Biosimilar Pharmaceuticals / Infliximab / Anti-Inflammatory Agents Type of study: Guideline Limits: Humans Language: En Journal: Rev Esp Enferm Dig Journal subject: GASTROENTEROLOGIA Year: 2018 Type: Article